言語を選択

BTLA

BTLA 詳細

英語名	B- and T-lymphocyte attenuator	市販薬剤の数	0
治験薬の数	6	ターゲットの別称	BTLA，B- and T-lymphocyte attenuator，B- and T-lymphocyte-associated protein，B And T Lymphocyte Associated，CD272 Antigen，BTLA1，CD272
研究＆開発段階	Phase 3 Clinical

英語名	B- and T-lymphocyte attenuator
ターゲットの別称	BTLA，B- and T-lymphocyte attenuator，B- and T-lymphocyte-associated protein，B And T Lymphocyte Associated，CD272 Antigen，BTLA1，CD272
市販薬剤の数	0
治験薬の数	6
研究＆開発段階	Phase 3 Clinical

BTLA 製品リスト

属性
Protein (10)Cell (2)Antibody (1)
製品ライブラリ
オンライン (13)
種
Human (11)Mouse (2)
タグ
Fc Tag (3)His Tag (3)Fc Tag & Avi Tag (1)Mouse IgG Fc Tag (1)His Tag & Avi Tag (2)- (3)
マーカー
Unconjugated (7)Biotin-labeled (3)- (2)PE Labeled (1)

製品番号	種	発現システム	製品説明
HOT BTA-H52H3	Human	HEK293	Human BTLA (31-150) Protein, His Tag, low endotoxin (MALS verified)
HOT BTA-H82E4	Human	HEK293	Biotinylated Human BTLA (31-150) Protein, His,Avitag™ (MALS verified)
HOT BTA-H82E5	Human	HEK293	Biotinylated Human BTLA (31-150) (M105V, G138S, V148M) Protein, His,Avitag™ (MALS verified)
HOT BTA-M52E2	Mouse	HEK293	Mouse BTLA Protein, His Tag
BTA-H5254	Human	HEK293	Human BTLA (31-150) (M105V, G138S, V148M) Protein, Fc Tag (MALS verified)
BTA-H5255	Human	HEK293	Human BTLA (31-134) Protein, Fc Tag
BTA-H5256	Human	HEK293	Human BTLA (31-150) Protein, Fc Tag (MALS verified)
BTA-H5258	Human	HEK293	Human BTLA (31-150) Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)
BTA-H52H5	Human	HEK293	Human BTLA (31-150) (M105V, G138S, V148M) Protein, His Tag (MALS verified)
BTA-H82F3	Human	HEK293	Biotinylated Human BTLA (31-150) Protein, Fc,Avitag™ (MALS verified)

総数量13

BTLAバックグランド

B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

BTLA分子の別称

BTLA,CD272

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Tifcemalimab	JS-004; TAB-004	Phase 3 Clinical	Shanghai Junshi Biosciences Co Ltd	Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Hodgkin Disease; Lung Neoplasms; Lymphoma; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms	詳細
MB-272	MB272; GS-0272	Phase 1 Clinical	MiroBio Ltd, University Of Oxford	Arthritis, Rheumatoid; Autoimmune Diseases	詳細
ANB-032	ANB-032	Phase 1 Clinical	Anaptysbio Inc	Dermatitis, Atopic; Eczema; Inflammation	詳細
Venanprubart	LY-3361237	Phase 1 Clinical	Eli Lilly And Company, Sanford-Burnham Medical Research Institute	Lupus Erythematosus, Systemic; Psoriasis; Sjogren's Syndrome	詳細
HFB200604 AID	HFB-200604-AID; HFB200604; HFB-200604; HFB200604 AID	Phase 1 Clinical	HiFiBiO Therapeutics	Autoimmune Diseases; Inflammation	詳細
HFB-200603	HFB-200603	Phase 1 Clinical	HiFiBiO Therapeutics	Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma; Neoplasms; Stomach Neoplasms	詳細